LENSAR, Inc.
Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
About
CEO
Mr. Nicholas T. Curtis
Employees
130
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNCM
Address
2800 Discovery Drive, Orlando, FL 32826, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Mar 3, 2025 | -0.21 | — | — | — |
| Nov 7, 2024 | -0.29 | -0.13 | 0.16 | -55.17% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 2 |
| Average estimate | — | -0.23 | — | -0.57 |
| Low estimate | — | -0.28 | — | -0.59 |
| High estimate | — | -0.17 | — | -0.55 |
| Last year EPS | — | -0.19 | — | -1.29 |
[stock_revenue_estimate]
Growth estimates
Current qtr
48.570%
Next qtr. (Mar 2025)
-18.420%
Current year
1.910%
Next year (Dec 2025)
55.640%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 42.16M | 35.36M | 34.46M | 26.38M | 30.53M |
| Cost of revenue | 21.06M | 15.40M | 16.63M | 12.31M | 17.30M |
| Gross profit | 21.11M | 19.96M | 17.83M | 14.08M | 13.23M |
| Operating expense | |||||
| Research & development | 6.14M | 11.81M | 12.36M | 7.55M | 7.57M |
| Selling general and admin | 26.10M | 27.17M | 23.89M | 23.77M | 17.15M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -12.23M | -20.18M | -19.65M | -18.50M | -12.71M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | — | — | — | 1.34M | 2.00M |
| Other income expense | -2.15M | 263,000 | 51,000 | 68,000 | 58,000 |
| Pretax income | -14.38M | -19.91M | -19.60M | -19.77M | -14.66M |
| Tax provision | — | — | — | — | — |
| Net income | -14.38M | -19.91M | -19.60M | -19.77M | -14.66M |
| Basic EPS | -1.31 | -1.96 | -2.09 | -4.28 | -1.38 |
| Diluted EPS | -1.31 | -1.96 | -2.09 | -4.28 | -1.38 |
| Basic average shares | 10.97M | 10.16M | 9.37M | 4.62M | 10.63M |
| Diluted average shares | 10.97M | 10.16M | 9.37M | 4.62M | 10.63M |
| EBITDA | -5.86M | -16.77M | -16.89M | -15.87M | -8.79M |
| Net income from continuing op. | -14.38M | -19.91M | -19.60M | -19.77M | -14.66M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 69.59M | 55.84M | 66.47M | 79.12M | 34.54M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 20.62M | 14.67M | 31.64M | 40.60M | 4.62M |
| Other short term investments | 3.44M | — | — | — | — |
| Accounts receivable | 4.00M | 6.04M | 4.64M | 2.01M | 3.38M |
| Other receivables | — | — | — | — | — |
| Inventory | 15.69M | 11.74M | 6.49M | 13.47M | 8.06M |
| Prepaid assets | — | — | 1.70M | 1.86M | 618,000 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 2.37M | 1.06M | 1.70M | 1.86M | 618,000 |
| Non current assets | |||||
| Properties | 19.25M | 16.98M | 15.65M | 11.06M | 2.87M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 478,000 | 430,000 | 246,000 | 195,000 | — |
| Construction in progress | 188,000 | 55,000 | 184,000 | 680,000 | — |
| Leases | 112,000 | 112,000 | 112,000 | 112,000 | — |
| Accumulated depreciation | -11.89M | -10.69M | -8.74M | -7.64M | — |
| Goodwill | 11.03M | 12.12M | 10.87M | 12.11M | 13.37M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 11.03M | 12.12M | 10.87M | 12.11M | 13.37M |
| Investments and advances | 492,000 | — | — | — | — |
| Other non current assets | 2.21M | 2.69M | 3.22M | 3.76M | 1.01M |
| Total liabilities | 36.16M | 13.86M | 11.59M | 11.91M | 65.09M |
| Current liabilities | |||||
| Accounts payable | 4.01M | 5.42M | 2.69M | 2.48M | 1.58M |
| Accrued expenses | 1.71M | 1.18M | 1.23M | 1.60M | 806,000 |
| Short term debt | 559,000 | 531,000 | 512,000 | 493,000 | — |
| Deferred revenue | 1.38M | 939,000 | 904,000 | 923,000 | 777,000 |
| Tax payable | — | — | — | — | — |
| Pensions | 3.97M | 3.35M | 3.38M | 2.97M | 3.97M |
| Other current liabilities | — | — | — | 493,000 | 697,000 |
| Non current liabilities | |||||
| Long term debt | 1.75M | 2.27M | 2.80M | 3.31M | 20.53M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 8.46M | — | — | — | — |
| Other non current liabilities | 570,000 | 167,000 | 69,000 | 129,000 | 310,000 |
| Shareholders equity | |||||
| Common stock | 113,000 | 111,000 | 110,000 | 109,000 | 11,000 |
| Retained earnings | -111.89M | -97.51M | -77.59M | -57.99M | -38.19M |
| Other shareholders equity | 4,000 | — | — | — | — |
| Total shareholders equity | 33.43M | 41.98M | 54.88M | 67.21M | -30.55M |
| Additional paid in capital | 145.20M | 139.38M | 132.36M | 125.09M | 7.62M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -14.38M | -19.91M | -19.60M | -19.77M | -14.66M |
| Depreciation | 3.52M | 3.41M | 2.76M | 2.57M | 3.87M |
| Deferred Taxes | — | — | — | — | — |
| Stock-Based Compensation | 5.54M | 6.61M | 6.87M | 9.05M | 102,000 |
| Other Non-Cash Items | 534,000 | 521,000 | 517,000 | 505,000 | 537,000 |
| Accounts Receivable | 1.08M | -1.62M | -2.65M | 1.33M | 14,000 |
| Accounts Payable | -1.42M | 2.73M | 213,000 | 910,000 | 127,000 |
| Other Assets & Liabilities | -7.03M | -7.42M | 2.17M | -8.06M | -4.38M |
| Operating Cash Flow | -12.16M | -15.69M | -9.73M | -13.48M | -14.39M |
| Investing Activities | |||||
| Capital Expenditures | -236,000 | -115,000 | -354,000 | -326,000 | -389,000 |
| Net Intangibles | — | — | — | — | -1.70M |
| Net Acquisitions | — | — | — | — | — |
| Purchase of Investments | -3.92M | — | — | — | — |
| Sale of Investments | — | — | — | — | — |
| Investing Cash Flow | -4.16M | -115,000 | -354,000 | -326,000 | -389,000 |
| Financing Activities | |||||
| Long-Term Debt Issuance | — | — | — | 12.40M | 13.23M |
| Long-Term Debt Payments | — | — | — | — | — |
| Other Financing Charges | — | -2.40M | — | — | -1.07M |
| Financing Cash Flow | 13.88M | -2.40M | — | 50.00M | 15.95M |
| Other Cash Details | |||||
| End Cash Position | 20.62M | 14.67M | 31.64M | 40.60M | 4.72M |
| Income Tax Paid | 18,000 | 3,000 | 19,000 | — | — |
| Interest Paid | — | — | — | 478,000 | 473,000 |
| Free Cash Flow | -9.90M | -14.97M | -9.32M | -14.16M | -14.68M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 282,930 | 3.28M | 2.44% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 133,235 | 1.54M | 1.15% |
| DFA U.S. Targeted Value Portfolio | Oct 31, 2024 | 112,330 | 1.30M | 0.97% |
| DFA U.S. Small Cap Series | Oct 31, 2024 | 102,775 | 1.19M | 0.88% |
| Brandes Small Cap Value Fund | Sep 30, 2024 | 94,178 | 1.09M | 0.81% |
| DFA U.S. Small Cap Value Series | Oct 31, 2024 | 91,761 | 1.06M | 0.79% |
| DFA U.S. Micro Cap Series | Oct 31, 2024 | 81,309 | 942,371 | 0.70% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 54,329 | 629,673 | 0.47% |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | Oct 31, 2024 | 51,115 | 592,422 | 0.44% |
| DFA U.S. Vector Equity Portfolio | Oct 31, 2024 | 38,325 | 444,186 | 0.33% |
Article
Medical Devices Firm Lensar Surges Ahead On Robotic Technology
LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company's ALLY Robotic Cataract Laser System has driven significant revenue and earnings growth, with a one-year price target of $15.15, a 42.21% increase. Despite competition from larger firms, LENSAR's disruptive technology, expanding market share, and strong management team position it well for long-term growth.
Feb 5, 2025
Article
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of February 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Feb 4, 2025
Article
LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors.
Nov 26, 2024
